(in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $99.7 | $117.7 | $116.89 | $129.41 |
Short term investments | ||||
Net receivables | ||||
Inventory | ||||
Total current assets | $103.87 | $120.09 | $119.79 | $132.41 |
Long term investments | ||||
Property, plant & equipment | ||||
Goodwill & intangible assets | ||||
Total noncurrent assets | ||||
Total investments | ||||
Total assets | $124.54 | $141.55 | $142.09 | $155.53 |
Current liabilities | ||||
Accounts payable | $4.14 | $7.69 | $8.58 | $2.32 |
Deferred revenue | ||||
Short long term debt | ||||
Total current liabilities | $32.25 | $31.15 | $35.12 | $24.1 |
Long term debt | $0.03 | $14.07 | ||
Total noncurrent liabilities | ||||
Total debt | ||||
Total liabilities | $46.41 | $45.57 | $36.11 | $25.18 |
Shareholders' equity | ||||
Retained earnings | -$290.2 | -$266.34 | -$248.41 | -$219.28 |
Other shareholder equity | $0.34 | $0.78 | $0.36 | $0.64 |
Total shareholder equity |
(in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
---|---|---|---|---|
Current assets | ||||
Cash | $99.7 | $142.14 | $133.54 | $80.09 |
Short term investments | ||||
Net receivables | ||||
Inventory | ||||
Total current assets | $103.87 | $146.06 | $137.22 | $81.52 |
Long term investments | ||||
Property, plant & equipment | ||||
Goodwill & intangible assets | ||||
Total noncurrent assets | ||||
Total investments | ||||
Total assets | $124.54 | $169.99 | $164 | $81.52 |
Current liabilities | ||||
Accounts payable | $4.14 | $2.11 | $4.18 | $2.02 |
Deferred revenue | ||||
Short long term debt | ||||
Total current liabilities | $32.25 | $17.89 | $10.41 | $3.01 |
Long term debt | $0.03 | |||
Total noncurrent liabilities | ||||
Total debt | ||||
Total liabilities | $46.41 | $19.08 | $12.34 | $5.65 |
Shareholders' equity | ||||
Retained earnings | -$290.2 | -$194.47 | -$137.67 | -$44.64 |
Other shareholder equity | $0.34 | $0.63 | $1.05 | $0.28 |
Total shareholder equity |
(in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
---|---|---|---|---|
Revenue | ||||
Total revenue | ||||
Cost of revenue | ||||
Gross Profit | ||||
Operating activities | ||||
Research & development | ||||
Selling, general & administrative | ||||
Total operating expenses | ||||
Operating income | ||||
Income from continuing operations | ||||
EBIT | ||||
Income tax expense | ||||
Interest expense | ||||
Net income | ||||
Net income | ||||
Income (for common shares) |
(in millions $) | 31 Jan 2022 | 30 Jan 2021 | 31 Jan 2020 | 1 Oct 2018 |
---|---|---|---|---|
Revenue | ||||
Total revenue | ||||
Cost of revenue | ||||
Gross Profit | ||||
Operating activities | ||||
Research & development | ||||
Selling, general & administrative | ||||
Total operating expenses | $93.85 | $5.43 | $0.88 | |
Operating income | ||||
Income from continuing operations | ||||
EBIT | ||||
Income tax expense | -$1.16 | |||
Interest expense | -$0.45 | $0.03 | $0 | |
Net income | ||||
Net income | -$93.04 | -$35.34 | -$5.47 | -$0.88 |
Income (for common shares) |
(in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
---|---|---|---|---|
Net income | ||||
Operating activities | ||||
Depreciation | ||||
Business acquisitions & disposals | ||||
Stock-based compensation | ||||
Total cash flows from operations | ||||
Investing activities | ||||
Capital expenditures | ||||
Investments | ||||
Total cash flows from investing | -$0.3 | |||
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | ||||
Net borrowings | ||||
Total cash flows from financing | $58.63 | $0.42 | -$0.17 | $98.82 |
Effect of exchange rate | -$0.36 | -$0.23 | -$0.04 | $0.74 |
Change in cash and equivalents | $20.98 | -$27.8 | -$13.07 | $53.44 |
(in millions $) | 31 Jan 2022 | 30 Jan 2021 | 31 Jan 2020 | 1 Oct 2018 |
---|---|---|---|---|
Net income | ||||
Operating activities | ||||
Depreciation | ||||
Business acquisitions & disposals | ||||
Stock-based compensation | ||||
Total cash flows from operations | ||||
Investing activities | ||||
Capital expenditures | ||||
Investments | ||||
Total cash flows from investing | -$0.3 | $0.55 | ||
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | ||||
Net borrowings | ||||
Total cash flows from financing | $98.82 | $9.9 | $0.32 | |
Effect of exchange rate | $0.74 | $0.02 | ||
Change in cash and equivalents | $53.44 | $6.7 | $0.16 |
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
Zacks via Yahoo Finance
8 Mar 2024
|
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's...
Investing.com
7 Mar 2024
|
S&P 500 Gains 1%; Kroger Earnings Top Views - Brera Holdings (NASDAQ:BREA), Avid Bioservices...
Benzinga
7 Mar 2024
|
MindMed's MM120 shows promise in GAD treatment
Investing.com
7 Mar 2024
|
MindMed announces $175 million share offering
Investing.com
7 Mar 2024
|
11 Best Psychedelic Stocks to Buy in 2024
Insider Monkey via Yahoo Finance
29 Dec 2023
|
11 Most Promising Psychedelic Stocks According to Hedge Funds
Insider Monkey via Yahoo Finance
20 Dec 2023
|
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
Zacks via Yahoo Finance
20 Dec 2023
|
10 Stocks That Will Go Up 1000 Percent
Insider Monkey via Yahoo Finance
29 Jul 2023
|
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
Zacks via Yahoo Finance
18 May 2023
|
Market cap | $390.46M |
---|---|
Enterprise value | N/A |
Shares outstanding | 41.10M |
Revenue | N/A |
---|---|
EBITDA | N/A |
EBIT | N/A |
Net Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
P/E ratio | N/A |
---|---|
EV/Sales | N/A |
EV/EBITDA | N/A |
EV/EBIT | N/A |
P/S ratio | N/A |
P/B ratio | N/A |
Book/Share | N/A |
Cash/Share | 2.43 |
EPS | N/A |
---|---|
ROA | N/A |
ROE | N/A |
Debt/Equity | N/A |
---|---|
Net debt/EBITDA | N/A |
Current ratio | 3.22 |
Quick ratio | N/A |